

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1150348
<b>Application Number:</b>	10049587
<b>Confirmation Number:</b>	9701
<b>Title of Invention:</b>	Orally active peptides that prevent cell damage and death
<b>First Named Inventor:</b>	Douglas E. Brenneman
<b>Correspondence Address:</b>	Annette S Parent Townsend and Townsend and Crew Two Embarcadero Center 8th Floor - San Francisco CA 94111-3834 US - -
<b>Filer:</b>	Aaron Hokamura
<b>Filer Authorized By:</b>	
<b>Attorney Docket Number:</b>	15280W-0021US
<b>Receipt Date:</b>	10-AUG-2006
<b>Filing Date:</b>	12-FEB-2002
<b>Time Stamp:</b>	20:37:44
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 630

RAM confirmation Number	566
Deposit Account	201430
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17	

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1		Amendment.pdf	176485	yes	17
	Multipart Description				
	Doc Desc		Start	End	
	Amendment - After Non-Final Rejection		1	1	
	Specification		2	2	
	Claims		3	13	
	Applicant Arguments/Remarks Made in an Amendment		14	17	
Warnings:					
Information:					
2	Extension of Time	Extension.pdf	107615	no	1
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Filed	IDS.pdf	323326	no	8
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
4	Foreign Reference	WO9218140.pdf	1079347	no	36
Warnings:					
Information:					
5	Foreign Reference	WO9611948.pdf	2416224	no	61
Warnings:					
Information:					

6	Foreign Reference	WO9835042.pdf	6312488	no	121
<b>Warnings:</b>					
<b>Information:</b>					
7	Foreign Reference	WO0027875.pdf	7298788	no	136
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	WO0053217.pdf	3513944	no	65
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	WO0112654.pdf	3906230	no	88
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	EP1206489B1.pdf	470089	no	56
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	Bassan_JNeuro_v72_p1283_1999.pdf	273781	no	11
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	Bassan_RegPeptides_v71_1997.pdf	76327	no	1
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	BeniAdani_SocNeuroMtg_v23_p1043_1998.pdf	265565	no	2
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	Brenneman_DevBrainRes_v51_p63_1990.pdf	546258	no	6
<b>Warnings:</b>					
<b>Information:</b>					

15	NPL Documents	Brenneman_JClinInvest_v97_p2299_1996.pdf	224647	no	9
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	Brenneman_JPET_v285_p619_1998.pdf	129526	no	9
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	Brenneman_Nature_v335_p636_1988.pdf	543831	no	4
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	Brenneman_SocNeuroMtg_v23_p2250_1997.pdf	251704	no	3
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	Dibbern_JCI_v99_p2837_1997.pdf	170080	no	5
<b>Warnings:</b>					
<b>Information:</b>					
20	NPL Documents	GenBank_AB018327.pdf	165574	no	3
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Davidson_SocNeuroMtg_v23_p2250_1997.pdf	262744	no	3
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Giladi_NeuroSciLett_Supp48_1997.pdf	130642	no	1
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Glazner_AnatEmbryol_v200_p65_1999.pdf	754104	no	7
<b>Warnings:</b>					
<b>Information:</b>					

24	NPL Documents	Glazner_SocNeuroMtg_v23_p2249_1997.pdf	268635	no	3
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Gozes_AnnalsNYAcadSci_v897_p125_1999.pdf	286371	no	6
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Gozes_DevBrainRes_v99_p167_1997.pdf	771444	no	9
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Gozes_Endocrinology_v134_p2125_1994.pdf	519046	no	5
<b>Warnings:</b>					
<b>Information:</b>					
28	NPL Documents	Gozes_JMolNeurosci_v7_p235_1996.pdf	933290	no	10
<b>Warnings:</b>					
<b>Information:</b>					
29	NPL Documents	Gozes_JNeuro_v33_p329_1997.pdf	1214380	no	14
<b>Warnings:</b>					
<b>Information:</b>					
30	NPL Documents	Gozes_JPET_v273_p161_1995.pdf	698683	no	7
<b>Warnings:</b>					
<b>Information:</b>					
31	NPL Documents	Gozes_JPET_v293_p1091_2000.pdf	143524	no	8
<b>Warnings:</b>					
<b>Information:</b>					
32	NPL Documents	Gozes_NeurosciLett_Supp48_1997.pdf	132231	no	1
<b>Warnings:</b>					
<b>Information:</b>					

33	NPL Documents	Gozes_PNAS_v93_p427_1996.pdf	1476770	no	6
<b>Warnings:</b>					
<b>Information:</b>					
34	NPL Documents	Gozes_SocNeuroMtg_v23_p2250_1997.pdf	244473	no	3
<b>Warnings:</b>					
<b>Information:</b>					
35	NPL Documents	Gressens_Nature_v362_p155_1993.pdf	546274	no	4
<b>Warnings:</b>					
<b>Information:</b>					
36	NPL Documents	Hannigan_NeurotoxTeratol_v22_p103_2000.pdf	976235	no	9
<b>Warnings:</b>					
<b>Information:</b>					
37	NPL Documents	Hill_SocNeuroMtg_v23_p2250_1997.pdf	240705	no	3
<b>Warnings:</b>					
<b>Information:</b>					
38	NPL Documents	Lilling_JMolNeurosci_v5_p231_1995.pdf	649393	no	9
<b>Warnings:</b>					
<b>Information:</b>					
39	NPL Documents	Mahato_JDrugTargeting_v4_p337_1997.pdf	35304	no	1
<b>Warnings:</b>					
<b>Information:</b>					
40	NPL Documents	McCune_SocNeuroMtg_v23_p2249_1997.pdf	267731	no	3
<b>Warnings:</b>					
<b>Information:</b>					
41	NPL Documents	Nagase_DNAResearch_v5_p277_1998.pdf	269977	no	10
<b>Warnings:</b>					
<b>Information:</b>					

42	NPL Documents	Nelbock_Science_v248_p1650_1990.pdf	497896	no	4
<b>Warnings:</b>					
<b>Information:</b>					
43	NPL Documents	Oberdoerster_FASEBJ_v12_A134_1998.pdf	39936	no	1
<b>Warnings:</b>					
<b>Information:</b>					
44	NPL Documents	Pelsman_SocNeuroMtg_v24_p1044_1998.pdf	278333	no	2
<b>Warnings:</b>					
<b>Information:</b>					
45	NPL Documents	Skolnick_TIBS_v18_p34_2000.pdf	758367	no	6
<b>Warnings:</b>					
<b>Information:</b>					
46	NPL Documents	Smith_AnnRevMicrobiol_v49_p807_1995.pdf	30433	no	1
<b>Warnings:</b>					
<b>Information:</b>					
47	NPL Documents	Spinney_MolMedToday_v5_p282_1999.pdf	124240	no	1
<b>Warnings:</b>					
<b>Information:</b>					
48	NPL Documents	Spong_FASEBJ_v13_pA881_1991.pdf	39984	no	1
<b>Warnings:</b>					
<b>Information:</b>					
49	NPL Documents	Spong_JPET_v297_p774_2001.pdf	256531	no	6
<b>Warnings:</b>					
<b>Information:</b>					
50	NPL Documents	Voet_Biochemistry2ndEd_p67.pdf	137196	no	2
<b>Warnings:</b>					
<b>Information:</b>					

51	NPL Documents	Wilkemeyer_PNAS_v100_p8 543_2003.pdf	275130	no	6
<b>Warnings:</b>					
<b>Information:</b>					
52	Fee Worksheet (PTO-875)	fee-info.pdf	8327	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			41520158		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					